公开(公告)号：US11364224B2

公开(公告)日：2022-06-21

申请号：US16718414

申请日：2019-12-18

申请人： UPSHER-SMITH LABORATORIES, LLC

发明人： Prabhu Prabhakara ,  Rajesh Ramesh Patil ,  Piyush Gupta ,  Rajeev Singh Raghuvanshi ,  Anil N. Namboodiripad

IPC分类号： A61K31/4045 ,  A61K9/08 ,  A61K9/00

摘要： The present application relates to a method of treating migraine or cluster headache in a human patient, said method comprising administering subcutaneously composition comprising sumatriptan or its pharmaceutically acceptable salt, in an amount equivalent to 3 mg sumatriptan base.

公开(公告)号：US20220387386A1

公开(公告)日：2022-12-08

申请号：US17833105

申请日：2022-06-06

申请人： UPSHER-SMITH LABORATORIES, LLC

发明人： Prabhu Prabhakara ,  Rajesh Ramesh Patil ,  Piyush Gupta ,  Rajeev Singh Raghuvanshi ,  Anil N. Namboodiripad

IPC分类号： A61K31/4045 ,  A61K9/08 ,  A61K9/00

摘要： The present application relates to a method of treating migraine or cluster headache in a human patient, said method comprising administering subcutaneously composition comprising sumatriptan or its pharmaceutically acceptable salt, in an amount equivalent to 3 mg sumatriptan base.

公开(公告)号：US10537554B2

公开(公告)日：2020-01-21

申请号：US15011357

申请日：2016-01-29

申请人： UPSHER-SMITH LABORATORIES, LLC

发明人： Prabhu Prabhakara ,  Rajesh Ramesh Patil ,  Piyush Gupta ,  Rajeev Singh Raghuvanshi ,  Anil N. Namboodiripad

IPC分类号： A61K31/4045 ,  A61K9/08 ,  A61K9/00

摘要： The present application relates to a method of treating migraine or cluster headache in a human patient, said method comprising administering subcutaneously composition comprising sumatriptan or its pharmaceutically acceptable salt, in an amount equivalent to 3 mg sumatriptan base.

公开(公告)号：US20200171000A1

公开(公告)日：2020-06-04

申请号：US16718414

申请日：2019-12-18

申请人： UPSHER-SMITH LABORATORIES, LLC

发明人： Prabhu Prabhakara ,  Rajesh Ramesh Patil ,  Piyush Gupta ,  Rajeev Singh Raghuvanshi ,  Anil N. Namboodiripad

IPC分类号： A61K31/4045 ,  A61K9/00 ,  A61K9/08

摘要： The present application relates to a method of treating migraine or cluster headache in a human patient, said method comprising administering subcutaneously composition comprising sumatriptan or its pharmaceutically acceptable salt, in an amount equivalent to 3 mg sumatriptan base.